CMBA
ABCL icon

C.M. Bidwell & Associates’s AbCellera Biologics ABCL Stock Holding History

C.M. Bidwell & Associates’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-758
Closed -$4.33K – 479
2023
Q4 		$4.33K Buy
758
+364
+92% +$1.69K ﹤0.01% 339
2023
Q3 		$1.81K Buy
+394
New +$2.4K ﹤0.01% 478
2022
Q3 		– Sell
-11,625
Closed -$124K – 475
2022
Q2 		$124K Hold
11,625
– – 0.1% 189
2022
Q1 		$113K Buy
+11,625
New +$110K 0.07% 221

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

C.M. Bidwell & Associates's ABCL Position: Q1 2024 in Review

C.M. Bidwell & Associates sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 758 shares — an estimated $4.33K sold.

C.M. Bidwell & Associates first reported a position in ABCL in Q1 2022 and held it in 4 quarters. The position peaked at $124K in Q2 2022. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • C.M. Bidwell & Associates reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 758 AbCellera Biologics shares in Q1 2024, an estimated $4.33K.
  • C.M. Bidwell & Associates first reported a position in AbCellera Biologics in Q1 2022 and held it in 4 quarters.
  • C.M. Bidwell & Associates's AbCellera Biologics position peaked at $124K in Q2 2022.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2024, filed 14 May 2024.